Skip to main content
Premium Trial:

Request an Annual Quote

Aurora, Acacia Settle Dispute, Cross-License Genomic Technologies

Premium

SAN DIEGO, Calif.--Aurora Biosciences and Acacia Biosciences announced that they have agreed to settle an intellectual property dispute by cross-licensing key genomic technologies. Under the agreement, Aurora licensed certain elements of its patented fluorescent protein technology to Acacia, and Acacia licensed elements of its Genome Reporter Matrix technology to Aurora. Aurora also withdrew a patent infringement suit filed against, but not yet served on, Acacia, and Acacia agreed not to challenge the validity or enforceability of the Aurora patents regarding the licensed fluorescent proteins.

Acacia's President and CEO, Bruce Cohen, called the cross-licensing agreement a "useful commercial step for the two companies and a critical milestone for the genomics industry." Cohen added that the agreement "sends a signal to collaborators and investors that biotechnology companies that are active in genomic research and drug discovery can resolve intellectual property differences in a productive manner that does not impair the ability to advance scientific and business objectives."

Filed under

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.